| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
13,284 |
12,941 |
$701K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
17,001 |
16,107 |
$585K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
19,940 |
18,972 |
$509K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
2,494 |
2,447 |
$294K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,109 |
2,029 |
$130K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,041 |
1,021 |
$96K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
654 |
644 |
$76K |
| 64493 |
|
879 |
793 |
$63K |
| 64635 |
|
335 |
304 |
$46K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
909 |
880 |
$39K |
| 80305 |
|
3,172 |
3,096 |
$26K |
| 64494 |
|
640 |
534 |
$24K |
| 99205 |
Prolong outpt/office vis |
251 |
240 |
$19K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,162 |
1,091 |
$18K |
| 99442 |
|
637 |
572 |
$17K |
| 20553 |
|
558 |
377 |
$14K |
| 64636 |
|
164 |
145 |
$12K |
| 27096 |
|
125 |
122 |
$9K |
| 20610 |
|
360 |
327 |
$8K |
| 76942 |
|
161 |
123 |
$4K |
| 64490 |
|
39 |
37 |
$3K |
| 0012A |
|
47 |
47 |
$2K |
| 99443 |
|
34 |
31 |
$2K |
| 99215 |
Prolong outpt/office vis |
37 |
37 |
$1K |
| 0011A |
|
53 |
52 |
$1K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,909 |
1,755 |
$1K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
379 |
369 |
$1K |
| 64491 |
|
26 |
25 |
$708.12 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
2,133 |
1,967 |
$426.42 |
| 20552 |
|
14 |
12 |
$365.09 |
| J3490 |
Unclassified drugs |
382 |
352 |
$227.13 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
21 |
21 |
$122.21 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
98 |
84 |
$89.68 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
448 |
411 |
$29.84 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
19 |
19 |
$14.16 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
14 |
12 |
$7.01 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
13 |
13 |
$0.06 |
| 91301 |
|
91 |
90 |
$0.00 |